Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

The Role of FGF23 and Asymmetric Dimethylarginine (ADMA) in Chronic Kidney Disease

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified March 2011 by Ankara Education and Research Hospital.
Recruitment status was:  Recruiting
Information provided by:
Ankara Education and Research Hospital Identifier:
First received: March 16, 2011
Last updated: NA
Last verified: March 2011
History: No changes posted
In chronic kidney disease calcium (Ca) and phosphate (P) metabolism disorders are very common and also they are one of the leading causes of morbidity in these population. FGF23 is a novel factor that contributes Ca-P disorders. It has been hypothesized that FGF 23 increase is mediated by asymmetric dimethylarginine (ADMA). The aim of the study is to evaluate this hypothesis.

Metabolic Diseases
Chronic Kidney Disease

Study Type: Observational
Study Design: Observational Model: Cohort

Resource links provided by NLM:

Further study details as provided by Ankara Education and Research Hospital:

Estimated Enrollment: 100
Study Start Date: March 2011
Group I
Stage 2 Non-diabetic Chronic Kidney Disease
Group II
Stage 3 Non-diabetic Chronic Kidney Disease
Group III
Stage 4 Non-diabetic Chronic Kidney Disease


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Stage 2-4 Non-diabetic Chronic Kidney Disease patients

Inclusion Criteria:

  • between ages of 18 - 65 years old
  • chronic kidney disease of stage 2-4

Exclusion Criteria:

  • presence of diabetes mellitus or ischemic hearth disease
  • taking vitamin d therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01317186

Ankara Education and Research Hospital Recruiting
Ankara, Turkey
Contact: Alper AZAK   
Contact: Bülent Huddam   
Sub-Investigator: Bülent Huddam         
Sponsors and Collaborators
Ankara Education and Research Hospital
  More Information

Responsible Party: Bülent Huddam, Ankara Education and Research Hospital Identifier: NCT01317186     History of Changes
Other Study ID Numbers: NEPH002
Study First Received: March 16, 2011
Last Updated: March 16, 2011

Keywords provided by Ankara Education and Research Hospital:
FGF 23
chronic kidney disease
Ca-P metabolism disorder

Additional relevant MeSH terms:
Renal Insufficiency, Chronic
Kidney Diseases
Metabolic Diseases
Renal Insufficiency
Urologic Diseases
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on May 25, 2017